Massive Change Could Be Looming for Specialty Pharmacy
May 2nd 2019During the featured session at Asembia’s Specialty Pharmacy Summit 2019, “Specialty Industry Outlook: What’s Next,†speakers Adam Fein, PhD, CEO of the Drug Channels Institute; Lisa Gill, managing director of J.P. Morgan Securities; and Doug Long, vice president of industry relations at IQVIA, explored the radical changes that could be on the horizon from potential legislation that would dramatically alter the health care industry.
Read More
Former FDA Commissioner Scott Gottlieb Talks Agency Innovation
May 2nd 2019At the Asembia Specialty Pharmacy Summit 2019, Scott Gottlieb, MD, 23rd commissioner of the FDA discussed the agency's role in rewriting the modern rules of new regulatory paradigms for a number of recent advancements in medicine.
Read More
Oncology Innovation Fueling Rapid Pipeline Growth
May 1st 2019The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.
Read More
Clinical Pearls Help Specialty Pharmacists Improve Pulmonary Arterial Hypertension Outcomes
April 30th 2019During a session on Monday at Asembia’s Specialty Pharmacy Summit 2019, experts discussed specialty pharmacy’s potential to improve outcomes for patients with pulmonary arterial hypertension.
Read More
IDH Inhibitor Use in Patients with Relapsed or Refractory AML
April 15th 2019In this clip, Bernard Marini, PharmD, BCOP, inpatient hematology specialist at the University of Michigan, discusses how IDH inhibitors like ivosidenib and enasidenib fit into the treatment landscape for patients with relapsed or refractory acute myeloid leukemia.
Read More
Considerations for Apalutamide Versus Enzalutamide in Prostate Cancer Treatment
April 9th 2019Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut, explains which patient populations would best benefit from either apalutamide versus enzalutamide in the treatment of non-metastatic prostate cancer.
Read More